FINWIRES · TerminalLIVE
FINWIRES

$PROF

4 stories mentioning PROFUpdated 20d ago

Every FINWIRES story that references PROF, newest first.

Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index up 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.7%.The iShares Biotechnology ETF (IBB) decreased 0.3%.In corporate news, Tenet Healthcare (THC) shares surged past 17% after it posted higher Q2 adjusted earnings and revenue, and raised its 2026 guidance.Novo Nordisk (NVO) is seeking a preliminary US court injunction to immediately block advertising by Eli Lilly (LLY) for its obesity and diabetes drugs, escalating the companies' legal dispute over weight-loss drug marketing, Reuters reported Friday. Novo shares rose 1.9%, and Lilly was up 0.6%.Profound Medical (PROF) said new data from a Level 1 evidence trial of its MRI-guided Tulsa procedure demonstrated statistically significant superiority over robotic radical prostatectomy in men with intermediate-risk prostate cancer. Its shares jumped past 8%.Lisata Therapeutics (LSTA) shares fell 16% after the company said it has terminated its planned merger with Kuva Labs.

$LLY$LSTA$NVO$PROF$THC
Sectors

Sector Update: Healthcare

Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index up 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.7%.The iShares Biotechnology ETF (IBB) decreased 0.3%.In corporate news, Profound Medical (PROF) said new data from a Level 1 evidence trial of its MRI-guided Tulsa procedure demonstrated statistically significant superiority over robotic radical prostatectomy in men with intermediate-risk prostate cancer. Its shares jumped past 8%.

$PROF
Wire

Profound Medical Reports New Statistically Significant Tulsa Trial Results; Shares Rise

Profound Medical (PROF) said new data from a Level 1 evidence trial of its MRI-guided Tulsa procedure demonstrated statistically significant superiority over robotic radical prostatectomy in men with intermediate-risk prostate cancer.At one month, patients treated with whole-gland Tulsa showed no median change in short-term physical outcomes, compared with a measurable reduction for robotic radical prostatectomy, the company said Friday in a statement.The findings add to previously reported trial results showing the procedure was superior to robotic prostatectomy in preserving erectile function and urinary continence at six months, Profound Medical said.Profound Medical shares rose 3.4% in Friday trading.Price: $7.08, Change: $+0.23, Percent Change: +3.36%

$PROF
Mining & Metals

Profound Medical Down 8.5% After Hours as Its Q1 Loss Narrows, Revenue More Than Doubles, Beats Estimates

Profound Medical (PRN.TO, PROF) was last seen down 8.5%% in after-hours New York trade after the company on Thursday reported a narrower first-quarter loss as revenue advanced, with both measures beating forecasts.The medical-device company said it lost US$7.0 million, or US$0.19 per share, in the quarter, compared to a loss of US$10.7 million, or US$0.36, in the prior year period. Analysts polled by FactSet had expected a loss of US$0.25 per share.Revenue jumped 104% to US$5.3 million over the same period, beating the US$4.9 million FactSet forecast. The company said it earned US$2.5 million revenue from recurring non-capital revenue, which consists of the sale of one-time use devices and services associated with extended warranties, and US$2.9 million from the one-time sale of capital equipment.The company projects total revenue for full-year 2026 to be approximately US$25 million, which represents 56% growth compared to its prior year revenue. The company also expects full year 2026 gross margin to be 70% or higher.Profound said its Profound's TULSA-PRO installed base stood at 80 at the end of Q1-2026, and the company shipped an additional six systems during the first quarter that had yet to be installed. It also announced that Humana has become the first national payor in the United States to cover the TULSA Procedure."We continued to execute well across our business in the first quarter, delivering triple-digit revenue growth combined with strong gross margin and lower operating expenses. We were also pleased to see statistically significant and clinically meaningful benefit from the TULSA Procedure beginning to readout from the randomized post-market CAPTAIN clinical trial comparing it to robotic radical prostatectomy, the current standard of care," said chief executive Arun Menawat.The company's shares were down US$0.61 to US$6.55 after hours trading after closing up C$0.14 to $9.75 on the Toronto Stock Exchange.

$PRN.TO$PROF

Track with the FINWIRES app suite

FolioX
FolioX
Track PROF in your portfolio
WheelAI
WheelAI
Analyze PROF options with the wheel strategy
StockInsider
StockInsider
See market sentiment on PROF